Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa

International Journal of Antimicrobial Agents

Volumn 24, Issue 6, 2004, Pages 529-535

  Zhanel, George G ^a,b,c   Hoban, Daryl J ^a,c   Schurek, Kristen ^a   Karlowsky, James A ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c SunnyBrook Regional Cancer Center   (Canada)

^d Focus Technologies Incorporated   (United States)

Author keywords

Efflux; Fluoroquinolone; Pseudomonas aeruginosa; Resistance; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 8844283457     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.08.003     Document Type: Short Survey

References (68)

1. G.G. Zhanel, K. Ennis, and L. Vercaigne A critical review of the fluoroquinolones: focus on respiratory infections Drugs 62 2002 13 59
2. J.A. Karlowsky, C. Thornsberry, M.E. Jones, A.T. Evangelista, I.A. Critchley, and D.F. Sahm Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002) Clin Infect Dis 36 2003 963 970
3. G.V. Doern, and S.D. Brown Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001 J Infect 48 2004 56 65
4. M.E. Jones, R.S. Blosser-Middleton, C. Thornsberry, J.A. Karlowsky, and D.F. Sahm The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002 Diagn Microbiol Infect Dis 47 2003 579 586
5. M.M. Neuhauser, R.A. Weinstein, R. Rydman, L.H. Danziger, G. Karam, and J.P. Quinn Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use JAMA 289 2003 885 888
6. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002. Issued August 2002. Am J Infect Control 2002;30:458-75.
7. J. Broskey, K. Coleman, and M.N. Gwynn Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae J Antimicrob Chemother 45 2000 95 99
8. M.A. Webber, and L.J. Piddock The importance of efflux pumps in bacterial antibiotic resistance J Antimicrob Chemother 51 2003 9 11
9. L. McMurry, R.E. Petrucci Jr., and S.B. Levy Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli Proc. Natl. Acad. Sci. U.S.A. 77 1980 3974 3977
10. P.R. Ball, S.W. Shales, and I. Chopra Plasmid-mediated tetracycline resistance in Escherichia coli involves increased efflux of the antibiotic Biochem Biophys Res Commun 93 1980 74 81
11. L.J. Piddock, and M.M. Johnson Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae Antimicrob Agents Chemother 46 2002 813 820
12. V.J. Heaton, C.E. Goldsmith, J.E. Ambler, and L.M. Fisher Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms Antimicrob Agents Chemother 43 1999 2998 3000
13. K.J. Madaras-Kelly, C. Daniels, M. Hegbloom, and M. Thompson Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae J Antimicrob Chemother 50 2002 211 218
14. N.P. Brenwald, M.J. Gill, and R. Wise The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin J Antimicrob Chemother 40 1997 458 460
15. H. Nikaido Antibiotic resistance caused by gram-negative multidrug efflux pumps Clin Infect Dis 27 1998 S32 S41
16. J.R. Aeschlimann The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other Gram-negative bacteria Pharmacotherapy 23 2003 916 924
17. M.E. Jones, J.A. Karlowsky, and R. Blosser-Middleton Longitudinal assessment of antipneumococcal susceptibility in the United States Antimicrob Agents Chemother 46 2002 2651 2655
18. R.N. Jones, and M.A. Pfaller Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY antimicrobial surveillance program (North America, 1997-1999) J Clin Microbiol 38 2000 4298 4299
19. G.G. Zhanel, L. Palatnick, K.A. Nichol, T. Bellyou, D.E. Low, and D.J. Hoban Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 Antimicrob Agents Chemother 47 2003 1867 1874
20. T.A. Davies, A. Evangelista, S. Pfleger, K. Bush, D.F. Sahm, and R. Goldschmidt Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000 Antimicrob Agents Chemother 46 2002 119 124
21. G.G. Zhanel, A. Walkty, K. Nichol, H. Smith, A. Noreddin, and D.J. Hoban Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada Diagn Microbiol Infect Dis 45 2003 63 67
22. M.J. Gill, N.P. Brenwald, and R. Wise Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae Antimicrob Agents Chemother 43 1999 187 189
23. H. Tettelin, K.E. Nelson, and I.T. Paulsen Complete genome sequence of a virulent isolate of Streptococcus pneumoniae Science 293 5529 2001 498 506
24. N.P. Brenwald, P. Appelbaum, T. Davies, and M.J. Gill Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae Clin Microbiol Infect 9 2003 140 143
25. N.P. Brenwald, M.J. Gill, and R. Wise Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 42 1998 2032 2035
26. K. Nagai, T.A. Davies, B.E. Dewasse, M.R. Jacobs, and P.C. Appelbaum Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae J Antimicrob Chemother 48 2001 365 374
27. A.P. Johnson, C.L. Sheppard, and S.J. Harnett Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England J Antimicrob Chemother 52 2003 953 960
28. L.J.V. Piddock, M.M. Johnson, S. Simgee, and L. Pumbwe Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 46 2002 808 812
29. P.L. Ho, R.W. Yung, and D.N. Tsang Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in. J Antimicrob Chemother 48 2001 659 665
30. L.J.V. Piddock, M. Johnson, V. Ricci, and S.L. Hill Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract Antimicrob Agents Chemother 42 1998 2956 2960
31. M.K. Lacy, W. Lu, and X. Xu Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection Antimicrob Agents Chemother 43 1999 672 677
32. G.G. Zhanel, M. Walters, N. Laing, and D.J. Hoban In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae J Antimicrob Chemother 47 2001 435 440
33. E.A. Coyle, G.W. Kaatz, and M.J. Rybak Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae Antimicrob Agents Chemother 45 2001 1654 1659
34. G.G. Zhanel, D. Roberts, and A. Waltky Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae J Antimicrob Chemother 49 2002 807 812
35. A.P. MacGowan, and K.E. Bowker Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model Antimicrob Agents Chemother 47 2003 1096 1100
36. P.D. Lister Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae Diagn Microbiol Infect Dis 44 2002 43 49
37. R.E. Hancock Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria Clin Infect Dis 27 1998 S93 S99
38. C.K. Stover, X.Q. Pham, and A.L. Erwin Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen Nature 406 6799 2000 959 964
39. NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990 to May 1999. Issued June 1999. Am J Infect Control 1999;27:520-32.
40. N. Masuda, E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa Antimicrob Agents Chemother 44 2000 3322 3327
41. H. Maseda, H. Yoneyama, and T. Nakae Assignment of the substrate-selective subunits of the MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa Antimicrob Agents Chemother 44 2000 658 664
42. Y. Li, T. Mima, and Y. Komori A new member of the tripartitie multidrug efflux pumps, Mex-VW-OprM, in Pseudomonas aeruginosa J Antimicrob Chemother 52 2003 572 575
43. O. Lomovskaya, A. Lee, and HoshinoF K. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa Antimicrob Agents Chemother 43 1999 1340 1346
44. L. Zhang, X.Z. Li, and K. Poole Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia J Antimicrob Chemother 48 2001 549 552
45. H. Oh, J. Stenhoff, S. Jalal, and B. Wretlind Role of efflux pumps and mutations in genes for topoisomerase II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains Microb Drug Resist 9 2003 323 328
46. A. Nakajima, Y. Sugimoto, H. Yoneyama, and T. Nakae High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation Microbiol Immunol 46 2002 391 395
47. P.G. Higgins, A.C. Fluit, D. Milatovic, J. Verhoef, and F.J. Schmitz Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa Int J Antimicrob Agents 21 2003 409 413
48. I. Le Thomas, G. Couetdic, O. Clermont, N. Brahimi, P. Plesiat, and E. Bingen In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy J Antimicrob Chemother 48 2001 553 555
49. S. Jalal, O. Ciofu, N. Hoiby, N. Gotoh, and B. Wretlind Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients Antimicrob Agents Chemother 44 2000 710 712
50. C. Llanes, D. Hocquet, C. Vogne, D. Benali-Baitich, C. Neuwirth, and P. Plesiat Clinical strains of Pseudomonas areuginosa overproducing Mex-AB-OprM and MexXY efflux pumps simultaneously Antimicrob Agents Chemother 48 2004 1797 1802
51. A. Lee, W. Mao, and M.S. Warren Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance J Bacteriol 182 2000 3142 3150
52. T. Kohler, M. Michea-Hamzehpour, P. Plesiat, A.-L. Kahr, and J.-C. Pechere Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa Antimicrob Agents Chemother 41 1997 2540 2543
53. O.F. Join-Lambert, M. Michea-Hamzehpour, and T. Kohler Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats Antimicrob Agents Chemother 45 2001 571 576
54. A.P. MacGowan, M. Wootton, and H.A. Holt The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility J Antimicrob Chemother 43 1999 345 349
55. K.J. Madaras-Kelly, A.J. Larsson, and J.C. Rotschafer A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa J Antimicrob Chemother 37 1996 703 710
56. N. Jumbe, A. Louie, and R. Leary Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy J Clin Invest 112 2003 275 285
57. G.L. Drusano, S.L. Preston, C. Fowler, M. Corrado, B. Wiesinger, and J. Kahn Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia J Infect Dis 189 2004 1590 1597
58. P.N. Markham Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine Antimicrob Agents Chemother 43 1999 988 989
59. V. Zeller, C. Janoir, M.-D. Kitzis, L. Gutmann, and N.J. Moreau Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae Antimicrob Agents Chemother 41 1997 1973 1978
60. T.E. Renau, R. Leger, and E.M. Flamme Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin J Med Chem 42 1999 4928 4931
61. A.Y. Coban, B. Ekinci, and B. Durupinar A multidrug efflux inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates Chemotherapy 50 2004 22 26
62. K. Nakayama, Y. Ishida, and M. Ohtsuka MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization Bioorg Med Chem Lett 13 2003 4201 4204
63. K. Nakayama, Y. Ishida, and M. Ohtsuka MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds Bioorg Med Chem Lett 13 2003 4205 4208
64. T.E. Renau, R. Leger, and L. Filonova Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa Bioorg Med Chem Lett 13 2003 2755 2758
65. T.E. Renau, R. Leger, and R. Yen Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa Bioorg Med Chem Lett 12 2002 763 766
66. W.J. Watkins, Y. Landaverry, and R. Leger The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors Bioorg Med Chem Lett 13 2003 4241 4244
67. H. Nikaido Multiple antibiotic resistance and efflux Curr Opin Microbiol 1 1998 516 523
68. M.H. Gotfried, L.H. Danziger, and K.A. Rodvold Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects Chest 119 2001 1114 1122